Abiopharma

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

OTC Markets Group Welcomes Surge Energy Inc. to OTCQX

ADP to Announce Fourth Quarter Fiscal 2026 Financial Results on July 29, 2026

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

VENU Joins Russell 3000 and Russell 2000 Indexes

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

SES AI Announces Inclusion in Russell 3000®Index